TCC1727 not checked
Beijing Tide Pharmaceutical Co., Ltd
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.”In the company’s words, NCT05970016 on ClinicalTrials.gov
- Tested for
- Patients with Advanced Solid Tumors, Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer, Malignant Melanoma
- Main trialPhase 1/2
- “This is a 2-part, phase I/II, open-label, multicenter study designed to evaluate the safety, PK, PD and preliminary efficacy of TCC1727 tablets administered orally QD.”In the company’s words, NCT05970016 on ClinicalTrials.gov
Other drugs for Patients with Advanced Solid Tumors
- PembrolizumabMerck & Co. · Phase 3
- EIK1001Eikon Therapeutics · Phase 2/3
- QL2107Qilu Pharmaceutical · Phase 3
- IFx-Hu2.0TuHURA Biosciences, Inc. · Phase 2/3
- FutibatinibTaiho · Phase 2/3
- MB11mAbxience Research S.L. · Phase 3
Coming up1
- 30 Sep 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Jul 2025 | A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. | |
| Phase 1/2Recruiting | 30 Sep 2028 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026